The lack of approved targeted therapies and effective chemotherapy with low toxicity for TNBC remains a major hindrance for treatment and prompted us to identify novel targets 8 . Using a bioinformatics approach based on patient-derived data, we showed that the transcription factor BACH1 is required for metastasis of aggressive TNBCs, and its gene signature is associated with poor outcomes [9] [10] [11] [12] . Of note, Bach1-null mice are viable and develop normally 13 , which suggests that BACH1 may be a good target for cancer therapy because it controls cellular stress responses but is not essential-and therefore may be inhibited with few side effects. TIMM17A  NDUFA9  COX15  SLC25A15  UQCRC1  SLC25A6  TIMM8B  ATP5J  SLC25A22  NDUFA2  PHB2  UCP3  COX18  OPA1  NDUFB6  NDUFS7  TIMM13  IMMT  ATP5B  HCCS  NDUFA6  NDUFAB1  PHB  AIFM3  UQCRB  HSD3B1  ATP5G1  ABCB7  ATP5G3  ATP5O 
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Fig. 1 | BACH1 inhibits mitochondrial genes in TNBC. a, Gene set enrichment analysis of BACH1-regulated genes with normalized enrichment score (NES) and false-discovery rate (FDR) Q value; heat map depicts changes in gene expression levels involved in 'mitochondrial inner membrane' , based on microarray data from BM1-shBACH1 and control cells (n = 3 biological replicates per cell line). Synonyms shown for: ATP5F1B (ATP5B), ATP5MC1 (ATP5G1), ATP5MC3 (ATP5G3), ATP5PO (ATP5O) and ATP5F1D (ATP5D). b, Left, relative mRNA levels of mitochondrial inner membrane genes in BM1-shBACH1 cells (two shBACH1 vectors) compared to the wild-type control (BM1-shCont) measured by qRT-PCR. Mean ± s.e.m., n = 3 biological independent replicates, two-tailed t-test. Right, protein blots of BACH1 and ETC genes in BM1-shBACH1 and control cell lysates. Relative band density shown below the blots. c, Representative BACH1 western blots using lysates of MB468, MB436 or BM1 cells. Each experiment repeated independently more than three times with similar results. d, Recruitment of BACH1 and H3K27Me3 to promoter regions of mitochondrial genes in BM1 cells. Relative fold enrichment compared to IgG binding shown as mean ± s.e.m., n = 3 biologically independent replicates, two-tailed t-test.
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to other subtypes such as luminal A, luminal B, HER2-enriched and normal-like breast cancer (Extended Data Fig. 1a, b) .
To examine other potential functions of BACH1 in TNBC, we evaluated microarrays of metastatic MDA-MB-231-derived cells (BM1; also termed 1833 (ref. 18 )) expressing short hairpin RNA (shRNA) for BACH1 (BM1-shBACH1) or control vector (BM1-shCont) 10 . Gene enrichment analysis identified a significant increase in metabolic pathways including energy metabolism and mitochondrial inner membrane genes upon BACH1 depletion ( Fig. 1a and Extended Data Fig. 1c ). We validated shBACH1 induction of mitochondrial inner membrane genes largely involved in the ETC by quantitative reverse transcription with PCR (qRT-PCR) and immunoblotting using two human TNBC cell lines that express BACH1: BM1 and MDA-MB-436 (MB436) (Fig. 1b and Extended Data Fig. 1d ).
To determine whether mitochondrial genes are direct BACH1 targets, we analysed potential BACH1 recruitment sites (MAF recognition elements) within the promoter regions of these genes 19 . Having identified potential BACH1-binding sites in six mitochondrial genes, ATP5D (also known as ATP5F1D), COX15, UQCRC1, ATP5J (also known as ATP5PF), SLC25A22 and TIMM8B (Extended Data Fig. 1e ), we performed chromatin immunoprecipitation (ChIP) assays with BACH1 antibody 20 . Haem oxygenase 1 (HMOX1), which is transcriptionally repressed by BACH1 13 , or BACH1-low cells (shBACH1 or MB468) served as positive or negative controls for BACH1-binding specificity ( Fig. 1c and Extended Data Fig. 1f ). We observed a marked enrichment of BACH1 binding to the promoter regions of ETC genes and binding of the repressive histone marker H3K27Me3 21 ( Fig. 1c, d and Extended Data Fig. 1g, h ). These results suggest that BACH1 is a direct suppressor of mitochondrial ETC gene transcription.
Further bioinformatics analyses using data from patients with breast cancer supported these findings. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of genes that negatively correlate with BACH1 expression in multiple breast cancer datasets showed a marked enrichment in oxidative phosphorylation gene expression as well as genes associated with other diseases (Extended Data Fig. 1i, j) . Furthermore, expression of ETC genes in TNBC-specific TCGA datasets was inversely correlated with BACH1 expression (Extended Data Fig. 1k and Supplementary Table 1) .
We then determined whether the BACH1-induced changes in ETC genes affect metabolic phenotypes in breast cancer cells by measuring both oxygen consumption rate (OCR), an indication of aerobic respiration, and extracellular acidification rate (ECAR), a readout of lactic acid produced from aerobic glycolysis. TNBC cells depleted of BACH1 displayed increased basal as well as maximum OCR but decreased ECAR relative to the control ( Fig. 2a and Extended Data Fig. 2a ). These data suggest that loss of BACH1 promotes mitochondrial respiration.
Consistent with these results, mass-spectrometry analysis of metabolites identified increased levels of TCA cycle intermediates and ATP levels upon BACH1 knockdown (Extended Data Fig. 2b) . We also observed a decrease in the steady-state levels of multiple intermediates in the glycolysis pathway, including glucose-6-phosphate (G6P), fructose-6-phosphate (F6P), fructose-1,6-bisphosphate (F16BP), dihydroxyacetone phosphate/glyceraldehyde 3-phosphate (DG3P) and lactate in shBACH1 cells.
To determine the effect of BACH1 on glucose utilization, we first treated shBACH1 cells with uniformly labelled [U- 13 C 6 ]-glucose 22 ( Fig. 2b) . We observed a significant increase in the levels of 13 C-labelled pyruvate in shBACH1 cells compared to control (Fig. 2c) . Similarly, the isotopomer distribution of [U- 13 C 6 ]-glucose into 13 C-labelled citrate, aconitate, α-ketoglutarate, fumarate and malate generally displayed a small but significant increase in shBACH1 cells relative to control cells ( Fig. 2d and Extended Data Fig. 2c) . A decrease in the labelling of the glycolytic intermediates 13 C-G6P and 13 C-glycerol-3-phosphate was also observed in shBACH1 cells relative to controls. We performed additional tracing with [U- 13 C 5 ]-glutamine, an alternative carbon source for mitochondria. In contrast to glucose utilization, we observed a small but significant decrease in isotopomer labelling of [U- 13 C 5 ]-glutamine in TCA intermediates upon BACH1 depletion (Extended Data Fig. 2d ). Collectively, these results suggest that loss of BACH1 induces ETC gene expression, promotes mitochondrial respiration and increases glucose utilization in the TCA cycle.
To better understand the changes in mitochondrial metabolism upon BACH1 depletion, we analysed an entry point into the TCA cycle, (Fig. 2e ). BACH1 knockdown reduces both PDK and PDH Ser293 phosphorylation (pSer293) but not overall PDH levels, thereby up-regulating PDH activity ( Fig. 2f and Extended Data Fig. 2e ). ChIP assays showed that BACH1 binds to the promoters of PDK genes in BM1 and MB436 but not in BACH1-deficient MB468 cells ( Fig. 2g and Extended Data Fig. 2f ). By contrast, there was no change in expression of pyruvate carboxylase, which replenishes TCA intermediates by converting pyruvate to oxaloacetate 25 (Extended Data  Fig. 2g ). These results indicate that BACH1 regulates PDK transcription and PDH phosphorylation, key steps controlling glycolysis and mitochondrial metabolism.
Because loss of BACH1 regulates mitochondrial metabolism, we determined whether BACH1-depleted cells exhibit increased sensitivity to agents that target these pathways. Metformin inhibits mitochondrial ETC complex I as well as other metabolic targets 5, 22, 26 . Rotenone and antimycin A target ETC complex I and complex III 27 , respectively. These inhibitors significantly reduced cell growth and viability in BACH1-depleted cells relative to control cells ( Fig. 2h and Extended Data Fig. 3a-c) . Cellular resistance to metformin at levels used in previous studies 28, 29 reflected the relative expression of BACH1 in MB468 (low), MB436 (intermediate) and BM1 (high) cells (Fig. 1c and Extended Data Fig. 3d, e) . As a widely prescribed anti-diabetic drug that can be cytostatic or cytotoxic 5, 30 , metformin is less toxic than rotenone or antimycin A; we therefore used metformin for further studies (Extended Data Fig. 3f ). These results suggest that BACH1 depletion overcomes TNBC resistance to inhibitors of mitochondrial metabolism by increasing dependency on mitochondrial respiration.
Additionally, we added pyruvate (2.5 mM) to BACH1-depleted cells to assess its effect on metformin resistance. Control cells (high BACH1) were resistant to metformin independent of pyruvate, but shBACH1 cells were only resistant to metformin in the presence of pyruvate. The effect of pyruvate on the NAD + :NADH ratio paralleled metformin resistance (Extended Data Fig. 4a, b) , consistent with previous reports 22, 26 . The mitochondrial ETC genes induced in BACH1-depleted cells also affected metformin sensitivity. Silencing of COX15 or UQCRC1 in BACH1-depleted cells completely restored metformin resistance and rescued cell growth (Extended Data Fig. 4c, d) . Notably, neither expression of the metformin transporter (OCT1, encoded by SLC22A1) 31 nor mitochondrial biogenesis genes such as peroxisome proliferator-activated receptor gamma (PPARG, which encodes PPARγ) or peroxisome proliferator-activated receptor gamma coactivator1-alpha (PPARGC1A, which encodes PGC1α) 32 were altered by BACH1 depletion (Extended Data Fig. 4e ). These results demonstrate that increased mitochondrial ETC gene expression enhances sensitivity to ETC inhibitor treatment.
As an alternative means of depleting BACH1, we induced BACH1 degradation using hemin, the active ingredient of the FDA-approved drug Panhematin, which is used to treat acute porphyria 33, 34 . We treated TNBC cells with a dose that is neither cytotoxic nor inhibits growth, yet is still effective at reducing BACH1 levels (Extended Data Fig. 5a ). As observed with shBACH1, hemin increased mitochondrial gene expression and altered cellular metabolic phenotypes, inducing basal and maximum OCR but lowering ECAR (Fig. 3a, b and Extended Data Fig. 5b, c) . Similarly, hemin decreased growth and viability of TNBC cells upon treatment with metformin or other ETC inhibitors ( Fig. 3c and Extended Data Fig. 5d , e). These results indicate that pharmacological depletion using hemin mimics the phenotype induced by genetic knockdown of BACH1.
To test hemin specificity for BACH1, we generated a haem-resistant mouse BACH1 mutant (BACH1(mut)), which has cysteine to alanine point mutations in four C-terminal haem-binding sites that are required for haem binding, release of BACH1 from DNA for nuclear export and subsequent degradation 7, 35 ( Fig. 3d and Extended Data Fig. 5f ). BACH1(mut), when expressed in shBACH1 TNBC cells, rescues BACH1 function (Extended Data Fig. 5g, h ). However, in contrast to control or shRNA-resistant wild-type mouse BACH1, BACH1(mut)-expressing cells were resistant to hemin treatment with respect to metabolic properties and metformin sensitivity ( We then tested whether BACH1 is a useful therapeutic target in vivo. First, we treated BACH1-depleted xenograft TNBC tumours with metformin in the range commonly used for mouse studies (200-300 mg per kg (body weight)) 28, 29 . These doses result in mouse tumour and plasma metformin concentrations (3-12 μM) similar to those found in metformin-treated patients with diabetes (~10 μM range) 28, 29 . Neither BACH1-depletion nor metformin alone altered tumour size 
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Rel. mRNA levels Vehicle Hemin P = 0.08 and treated with hemin (20 μM) for 48 h. For qRT-PCR analyses in a, f, mean ± s.e.m., n = 3 biologically independent samples, two-tailed t-test. For cell growth assays in c, e, mean ± s.e.m., n = 6 biologically independent samples, two-tailed t-test. In c, e, arrow indicates when drugs were added.
compared to control tumours. Notably, metformin suppressed growth of xenograft tumours (BM1 or MB436) that stably express shBACH1, and most grafted mice were tumour-free ( Fig. 4a and Extended Data Fig. 6a-c ). This reduction in tumours was not a consequence of overall toxicity, as all mice in this and subsequent treatment groups exhibited no change in body weight (Extended Data Fig. 6d ). As in cultured cells, the BACH1-depleted tumour cells had low levels of BACH1, reduced PDH pSer293 and increased ETC protein levels (Extended Data Fig. 6e, f) . Depletion of BACH1 in MB436 tumours also suppressed lung metastasis, consistent with our previous observations with BM1 cells 10 (Extended Data Fig. 6g, h ). Combination treatment with hemin and metformin also suppressed tumour growth. After tumour formation, we treated BACH1-expressing TNBC cell lines (BM1 and MB436) or patient-derived xenografts (PDX) with hemin for ten days to degrade BACH1 before metformin treatment (Extended Data Fig. 7a-c) . Only the combined hemin-metformin treatment significantly suppressed tumour growth (Fig. 4b, c and Extended Data Fig. 7d-f) .
Next, to investigate the dependence of combined hemin-metformin treatment on BACH1, we performed BACH1-rescue experiments using BM1 or MB436-shBACH1 cells transfected with mouse BACH1(mut). In contrast to tumours expressing wild-type BACH1, which exhibited reduced growth with hemin-metformin treatment, BACH1(mut) xenograft tumours were resistant to the hemin-metformin treatment ( Fig. 4d and Extended Data Fig. 7g-i) . Similarly, overexpression of wild-type mouse BACH1 in shBACH1 cells also rescued the resistant phenotype and overcame tumour sensitivity to combined hemin-metformin treatment, which was insufficient to degrade the mouse BACH1 at the dose used (Extended Data Fig. 7j ). Taken together, these results show that hemin sensitizes TNBC tumours to metformin by degrading BACH1.
Bioinformatics analyses of clinical samples illustrate the relevance of these findings to patients with cancer. Approximately 40% of TCGA breast tumours express BACH1 at normal or intermediate levels; however, 60% of these tumours express either higher or lower than normal levels of BACH1 (Fig. 4e) . Within this subset, BACH1 levels are high in 36% of TNBC samples versus 26% of non-TNBC samples (Extended Data Fig. 8a ). Consistent with our preclinical results, BACH1 expression correlates inversely with ETC expression in individual patient tumours (Fig. 4e) . Notably, BACH1 mRNA expression is enriched not only in breast cancer, but also in many other types of cancer including lung, kidney, uterine and prostate cancer, and acute myeloid leukaemia (Extended Data Fig. 8b, c) . KEGG analyses of genes that negatively correlate with BACH1 expression in tumours from patients with prostate, pancreas, ovary, skin, liver or colon cancer showed a similar enrichment in oxidative phosphorylation ( Fig. 4f and Extended Data Fig. 8d ). We also noted inversely correlated expression of BACH1 and ETC genes such as UQCRC1 in tumours from these other cancer types (Extended Data Figs. 8e, 9a-d) . Together, patient data analyses suggest that BACH1 inhibition of mitochondrial ETC genes may be a common mechanism in cancer.
Our results highlight BACH1 as a key regulator of mitochondrial metabolism and a determinant of TNBC response to metformin treatment. The combination of the changes in ETC gene expression, Mean ± s.e.m., two-tailed t-test. e, Heat map from OncoPrint analysis demonstrating expression (z-scores) of BACH1 and ETC gene expression for each patient with breast cancer (TCGA provisional dataset, n = 1105). ATP5G2 and ATP5L also known as ATP5MC2 and ATP5MG, respectively. f, Heat map showing KEGG pathways that are negatively correlated with BACH1 levels across major TCGA cancers such as breast (n = 1105), TNBC (n = 115), prostate (n = 497), pancreas (n = 186), ovary (n = 606), skin (n = 472), lung (n = 586), liver (n = 371) and colon (n = 379). Values shown as −log(FDR) with Benjamini-Hochberg-corrected P values (FDR) using the GOseq package. Only KEGG pathways commonly enriched in all cancer types studied are on the heat map. g, Proposed model summary of BACH1 regulation of metabolic pathways by inhibiting mitochondrial membrane gene expression and PDH activity; targets of combination therapy by metformin (ETC) and hemin (BACH1) are shown.
Letter reSeArCH mitochondrial respiration, levels of both glycolytic and TCA metabolites, and PDK transcription and PDH phosphorylation are consistent with alterations in metabolic pathways and carbon-source use upon BACH1 loss. To our knowledge, the role of BACH1 as a regulator of metabolism has not previously been recognized or studied. Thus, the downstream mechanisms driving the metabolic alterations that we observe upon BACH1 depletion, such as the differences in glutamine and glucose utilization in the TCA cycle, open new areas for investigation. Whereas the targets of BACH1 that we have characterized reflect the most marked changes in enzymes that regulate mitochondrial metabolism, there may be other targets that could potentially affect mitochondrial metabolism in this way.
The marked inverse correlation between BACH1 and ETC gene expression in individual patients raises the possibility that these biomarkers may be useful for prediction of metformin therapeutic outcome. Our findings also suggest a potential combination therapeutic strategy by repurposing two FDA-approved drugs, hemin and metformin (Fig. 4g) . Targeting the BACH1 pathway represents a novel approach to enhance the efficacy of inhibitors of mitochondrial metabolism through restriction of metabolic plasticity. More generally, we propose reprogramming the metabolic network to decrease metabolic variance and increase the fraction of cells with increased dependence on mitochondrial respiration. This approach could also be applied to other tumour types that use BACH1 or other key regulators of mitochondrial metabolism.
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Cell cultures. Human breast cancer cell lines (MDA-MB-436, MDA-MB-468)
and nonmalignant mammary epithelial cells (MCF10A and 184A1) were obtained from ATCC, and BM1 cells were obtained from A. Minn (University of Pennsylvania) and cultured as previously described 9, 10, 18, 20 . Cancer cells were maintained in high-glucose DMEM (25 mM glucose, 4 mM glutamine, without pyruvate) supplemented with 10% FBS (VWR, 89510-085) and penicillinstreptomycin (100 U ml −1 , 100 mg ml
), but cultured in glucose-limited conditions (1-2.5 mM glucose) that mimic tumour microenvironment with 10% FBS and penicillin-streptomycin when treated with inhibitors. Stable knock-down of BACH1 was performed using a lentiviral construct containing shRNA targeting BACH1 (shBACH1 clone 1: TATGCACAGAAGATTCATAGG; shBACH1 clone 2: ATATCATGGATACAATCCAGC) 10 . Transfected breast cancer cells were selected with puromycin (0.2 μg ml −1 ) in growth medium for 10 days. Mycoplasma detection was routinely performed to ensure cells were not infected with mycoplasma using MycoAlert Detection kit (Lonza, LT07-218). Cell lines were authenticated by short tandem repeat analysis. qRT-PCR. Total RNA from cells and tumour samples was isolated using Trizol (Invitrogen) according to the manufacturer's instructions. and Bach1 WT sequences were cloned into pCDH for lentiviral transfection. ChIP assays. Two million cells were plated on 10-cm plates overnight before crosslinking with 10% formaldehyde for 10 min followed by quenching with glycine (0.125 mM) for 3 min. After washing cells with cold PBS, total cell lysates in ice were sonicated at 80% output for 10 s with a 10-s pause for 4 cycles and pre-cleared with IgG (Santa Cruz, sc-2028) for 1 h at 4 °C. Supernatants were precipitated with antibodies against BACH1 (AF5776, R&D System), RNA Pol II phosphoS5 (Abcam, ab5131), histone H3 tri methyl K27 (Abcam, ab6002) or IgG (normal mouse IgG, Santa Cruz, sc-2025) overnight at 4 °C and washed for PCR as previously described 20 . Primers for ChIP-PCR are shown in Extended Data Table 1 .
Immunoblotting. Whole-cell or tumour lysates were prepared using RIPA buffer (Sigma, R2078) with protease inhibitor cocktail set III (Millipore, 539134) and phosphatase inhibitors (SimpleStop1, Gold Biotechnology) at 4 °C and quantified using Bradford assays before blotting using antibodies for BACH1 (sc-271211, Santa Cruz), PDK1 (C47H1) (Cell Signaling, no. 3820), PDH (Cell Signaling, #2784), PDH [p-Ser293] (Novusbio, BB110-93479), ATP5D (Abcam, ab107077), SLC25A15 (Novus Biologicals, NBP2-20387), UQCRC1 (Abcam, ab118687), COX15 (Sigma, av46442-100UL), NDUFA9 (Abcam, ab14713), and α-tubulin (Santa Cruz, sc-28199). Blots were imaged, processed and quantified using a Licor Odyssey Fc, dual-mode imaging system (Licor). NAD + /NADH. NAD(H) was measured using the NAD + /NADH-Glo Assay kit (Promega, G9071) in accordance with the manufacturer's protocol. Metabolic phenotypes. ECAR and OCR were monitored using a Seahorse Bioscience Analyzer (XF24; University of Illinois at Chicago and XFe96; Biophysics Core Facility at University of Chicago) according to the manufacturer's instructions. Cells were seeded in 24-well plates at a density of 5 × 10 4 and 96-well plates at a density of 5-8 × 10 3 cells per well with growth medium for at least 18 h. The following day, medium was changed to base medium (DMEM, 143 mM NaCl, phenol red, pH 7.35). For ECAR analysis, cells were added with medium (2 mM glutamine, pH 7.35) and monitored every 3 min following successive administration of 10 mM of glucose, and inhibitors (1 μM oligomycin and 50 mM 2-deoxyglucose). For OCR analysis, cells were added with mito stress-test base medium (10 mM glucose, 2 mM glutamine, 1 mM pyruvate, pH 7.4) and monitored every 3 min following successive administration of inhibitors (2 μM oligomycin, 2 μM FCCP, or 0.5 μM rotenone/antimycinA). BCA protein assays were used to normalize metabolic rates to cell number. Lung metastasis. Whole fixed lungs were evaluated by serial sectioning every 100 μm and followed by haematoxylin and eosin ( for BM1 xenograft and PDX mice) was provided in drinking water ad libitum.
For BACH1-expressing TNBC PDX models, frozen PDX tumours (no. 2147 and no. 4195) 36 in 0.5 ml of sterile HBSS were prepared in a volume of 10-20 mm 3 . In brief, tumour fragments were implanted into the mammary fat pads of five-week-old SCID-beige mice following standard procedures. When tumours reached 50 mm 3 in volume, hemin (50 mg kg
, intraperitoneal injection) and metformin (300 mg kg
) in drinking water were administered until the end of experiment. Tumour growth was monitored weekly by caliper measurement in two dimensions to generate ellipsoid volumes using the equation of volume = 0.4 × (length × width 2 ). Tumour weight was measured at the end of drug treatment in all mouse experiments. Tumour size (volume and weight) was shown as mean ± s.e.m. with P values determined by two-tailed t-test or two-way ANOVA with multiple comparisons. Experimental end point was reached when tumour growth reached 2 cm in diameter. Body weights of all mice were monitored regularly before and after treatment. Mouse experiments were performed one time per tumour model. Statistics. Gene expression in patient data, qRT-PCR, ChIP assays, viability assays, metabolomics, tracing analyses and tumour sizes were analysed to compare values measured in control groups relative to shBACH1 or hemin-treated cells by twotailed student's t-test using GraphPad Prism v.7.0a software. In vitro experiments were independently repeated at least three times for statistical analyses. For ChIP assays, at least three independent biological replicates were used for relative enrichment of BACH1 on the designated promoter regions compared to IgG enrichment. For viability assays, at least six biological replicates of shBACH1 or hemin-treated cells were analysed to compare to shRNA control cells or vehicle-treated cells (shown 100%), respectively. For assays involving cell growth using IncuCyte Zoom or metabolic phenotype using Seahorse, P values were determined by paired twotailed t-test. For co-expression analyses using data from patients with cancer, Pearson's and Spearman's correlation coefficients were used. For in vivo mouse experiments, at least five mice were used for each experimental group. Mouse allocation to treatment groups was randomized when tumours reached palpable minimum size, and mice that failed tumour formation were excluded from the experiments. No blinding was done for drug treatment or tumour measurement. All the statistical analyses were validated by the Center for Research Informatics (CRI) at University of Chicago. Gene set analysis and gene set enrichment analysis. The R package GSA 37 was used to determine which gene sets were enriched in the shBACH1 phenotype.
Two hundred permutations were used to estimate FDR. Enriched gene sets with FDR-corrected P values higher than 5% were filtered out. After the initial enrichment analysis, positively correlated (enrichment score >0) and negatively correlated (enrichment score <0) were considered separately.
Gene set enrichment analysis (GSEA) was conducted on the desktop version of the GSEA software (v.2.2.3). The 'max-probe' option was used for collapsing expression values of genes with multiple probes. Gene-set size was limited to an arbitrary cut-off of up to 500 genes per set, and genes were ranked by significance as defined by FDR-corrected P value <5%. As above, 200 permutations were used to estimate FDR for GSEA analysis. Analysis of data from patients with breast cancer. For TCGA, BACH1 expression data (RNA Seq V2 RSEM) from 817 publicly available cases of breast cancer were downloaded from the cBioPortal website 38, 39 (https://www.cbioportal.org, accessed February 2017) in the form of z-score-transformed data. The clinical data associated with these breast cancer cases were also downloaded from the same website. The TNBC subpopulation within the breast cancer cases was determined by 'negative' status for the immunohistochemistry scores of ER (also known as ESR1), PR (also known as PGR) and HER2 (also known as ERBB2) genes (total of 83 cases). For the analysis of BACH1 expression across different Pam50 categories, TCGA breast cancer expression and clinical data were accessed and processed using the R package TCGAbiolinks 40 (installed through https://www.bioconductor.org). This analysis was done solely on cases for which Pam50 classification information was available (total of 522 cases: 98 basal, 58 HER2-enriched, 231 luminal-A, 127 luminal-B and 8 normal-like). Statistical significance of differential BACH1 expression between different Pam50 subgroups, as well as TNBC versus non-TNBC, were determined by two-tailed Student's t-test.
Comparison of BACH1 expression levels in different cancer types was conducted on the basis of expression values (log 2 ) obtained by RNA-sequencing analysis (RNA-seq) of BACH1 in the provisional TCGA datasets. All cases (complete and incomplete) were used for each cancer type. Genes that are negatively correlated with BACH1 were determined based on a Spearman coefficient cut-off of ± 0.3. These selected genes were then subjected to KEGG pathway-enrichment analysis either by over-represented DAVID (https://david.ncifcrf.gov/home.jsp) using Benjamini-corrected P value (FDR) or by the R package GOseq 41 using the default program of Wallenius P value with Benjamini-Hochberg-corrected P values (https://bioconductor.org/packages/release/bioc/html/goseq.html).
The frequency of tumours that have upregulated BACH1 expression with respect to their matched healthy tissue was determined using the online tool BioXpress 42 (https://hive.biochemistry.gwu.edu/bioxpress). Only those TCGA samples that have matched normal tissue expression data were used for this analysis.
For METABRIC, GSE2023 and GSE11121 datasets, the Breast Cancer Integrative Platform processed with uniform normalization methods was accessed for BACH1 analysis at https://omics.bmi.ac.cn/bcancer/ (accessed July 2017) 43 . Metabolomics profiling. As previously reported with metabolomics profiling, BACH1-depleted BM1 and control cells (2 × 10 6 cells) were cultured in 10-cm dishes with DMEM (10 mM glucose, 4 mM glutamine, 10% FBS) for 16 h and serum-starved for 2 h. Cells were washed with PBS three times, collected in 1 ml PBS per replicate, and flash-frozen 44 . For polar metabolites, cell pellets were extracted in a 40:40:20 mix of acetonitrile:methanol:water including 10 nM d3-15 N-serine (CIL) as an internal standard. Insoluble debris was separated by centrifugation at 13,000 r.p.m. for 10 min. Aliquots of extracts were then injected into an Agilent 6460 or 6430 QQQ-liquid chromatography-tandem mass spectrometry (LC-MS/MS) instrument. Separation of metabolites was achieved using normal-phase chromatography with a Luna 5-mm NH 2 column (Phenomenex) using a mobile phase (buffer A, acetonitrile, followed by buffer B, 95:5 water:acetonitrile) with the modifiers 0.1% formic acid or 0.2% ammonium hydroxide/ 50 mM ammonium acetate for positive and negative ionization mode, respectively. Each run used the same flow: 100% A at 0.2 ml min −1 for 5 min, followed by a gradient starting at 0% B and linearly increasing to 100% B in 15 min with a flow rate of 0.7 ml min , succeeded by an isocratic gradient of 100% B for 5 min at 0.7 ml min −1 before equilibrating for 5 min with 0% B at 0.7 ml min -1 . For non-polar metabolites, cell pellets were extracted in 3 ml chloroform: methanol (2:1) and 1 ml PBS along with internal standards dodecylglycerol (10 nmol, Santa Cruz Biotechnology) and pentadecanoic acid (10 nmol, SigmaAldrich). Organic and aqueous layers were separated via centrifugation (1,000g for 5 min) and the organic layer collected, dried under nitrogen and dissolved in 120 μl chloroform. For nonpolar metabolites, metabolomes were separated using reverse-phase chromatography with a Luna C5 column (50 mm × 4.6 mm with 5-μm-diameter particles, Phenomenex). Mobile phase A was 95:5 water:methanol and mobile phase B was 60:35:5 ratio of 2-propanol: methanol: water. The positive-ionization mode uses 0.1% formic acid and 5 mM ammonium formate. The negative mode uses 0.1% ammonium hydroxide. The flow rate started at 0.1 ml min -1 for 5 min to alleviate backpressure associated with injecting chloroform. The gradient began at 0% B and increased linearly to 100% B over the course of 45 min at a flow rate of 0.4 ml min -1 , followed by an isocratic gradient of 100% B for 17 min at 0.5 ml min -1 before equilibrating for 8 min at 0% B with a flow rate of 0.5 ml min -1 . Mass spectrometry analysis was performed with an electrospray ionization source on an Agilent 6430 or 6460 QQQ LC-MS/MS (Agilent Technologies). The capillary voltage was set to 3.0 kV, and the fragmentor voltage to 100 V. The drying gas temperature was 350 °C, flow rate was 10 l min -1 , and nebulizer pressure was 35 psi. Metabolites were identified by selected reaction monitoring of the transition from precursor to product ions at associated optimized collision energies and retention times as previously described 45 . Metabolites were quantified by integrating the area under the curve, and then normalized to internal standard values. C glutamine for 16 h and harvested in 80% methanol in water on dry ice. After a freeze-thaw cycle at −80 °C, cell supernatants were collected by centrifugation at 20,000g for 10 min and dried using a speed vac for 3 h for the further liquid chromatography-mass spectrometry (LC-MS) analysis. 13 C metabolic tracer analyses were performed as previously described 46, 47 . Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
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Extended Data Fig. 1 | BACH1 expression is high in patients  with TNBC and suppresses expression of ETC genes at their promoter. a, Left, BACH1 expression levels (determined by RNA-seq) with respect to relative DNA copy-number alterations in TCGA breast cancers (n = 1105). Middle, BACH1 expression (RNA-seq) in TNBC (n = 83) or basal (n = 98) breast cancers compared to non-TNBC (n = 734) or non-basal (n = 424) breast cancers using Pam50 classification of TCGA data. Right, breast cancer subtypes classified by Pam50 (n = 522 total, n = 98 basal, n = 58 HER2-enriched, n = 231 luminal-A, n = 127 luminal-B, n = 8 normal-like). Two-tailed t-test. b, BACH1 expression levels (by RNA-seq) in patients with TNBC compared to patients that did not have TNBC, using the datasets of patients with breast cancer of METABRIC (n = 2509), GSE2034 (n = 286) and GSE11121 (n = 200). Two-tailed t-test. c, Gene Ontology terms as determined by gene set analysis for cell components that are positively correlated with BACH1 depletion based on microarray analysis of BM1-shBACH1 cell transcripts. n = 3 biologically independent samples, FDR-corrected P < 0.05. d, Left, relative mRNA levels of mitochondrial inner membrane genes in MB436-shBACH1 cells (two shBACH1 vectors, clone 1, clone 2) compared to the wild type control (MB436-shCont). Data are mean ± s.e.m., n = 3 biologically independent samples, two-tailed t-test. Right, representative western blots of mitochondrial genes using MB436-shBACH1 or control cell lysates. Each experiment was repeated independently three times with similar results. Band density quantification is shown below the blots. e, Schematic showing proximal BACH1 binding on the promoter regions of mitochondrial membrane genes. TSS, transcription start site. Arrows, primers used for ChIP-PCR. f, ChIP assays showing relative fold enrichment of BACH1 recruitment to the HMOX1 promoter using BACH1-depleted TNBC (BM1 and MB436) or control cells. g, h, ChIP assays showing fold enrichment of BACH1 and H3K27me3 recruitment to the mitochondrial membrane genes in low-BACH1-expressing MB468 and MB436 cells. For ChIP assays in f-h, data are mean ± s.e.m., n = 3 biologically independent samples, two-tailed t-test. i, KEGG pathways demonstrating the negative correlation between BACH1 expression and oxidative phosphorylation in all patients with breast cancer (n = 1,105, left) and patients with TNBC (n = 119, right). FDR values (−log 10 (FDR)) are generated in the R package GOseq using the default program Wallenius P values with Benjamini−Hochberg-corrected P values. j, Expression of ETC genes (COX15, ATP5D and ATP5G2 (also known as ATP5MC2)) in TNBC compared to tumours from patients that did not have TNBC using multiple breast cancer datasets: METABRIC (TNBC n = 319, non-TNBC n = 1661), GSE2034 (TNBC n = 54, non-TNBC n = 232) and GSE11121 (TNBC n = 33, non-TNBC n = 150). P values are determined by twotailed t-test. k, Co-expression plots of UQCRC1 or ATP5D and BACH1 in TCGA breast cancer (n = 1105) or TNBC (n = 115) dataset. Pearson's and Spearman's correlation coefficients are shown. 
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